Prospective, randomized, controlled study of the effect of hormone replacement therapy on peripheral blood flow velocity in postmenopausal women

被引:32
作者
Lau, TK [1 ]
Wan, D
Yim, SF
Sanderson, JE
Haines, CJ
机构
[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Obstet & Gynaecol, Shatin, New Territories, Hong Kong
[2] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med, Shatin, New Territories, Hong Kong
关键词
hormone replacement therapy; peripheral artery; pulsatility index;
D O I
10.1016/S0015-0282(98)00148-4
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To investigate the effect of different types and methods of delivery of hormone replacement therapy (HRT) on peripheral vascular flow velocity in postmenopausal women. Design: A prospective, randomized, operator-blinded, controlled study. Setting: A hormone replacement clinic in a university teaching hospital. Patient(s): Sixty-eight women who had undergone surgical menopause. Intervention(s): No treatment, oral estrogen, continuous combined estrogen and progestogen, or percutaneous estrogen. Main Outcome Measure(s): The pulsatility indices of the brachial, dorsalis pedis, popliteal, and radial arteries were measured under standardized conditions before the commencement of HRT and after 2 and 6 months of treatment. Serum E-2 levels were measured at each visit. Result(s): There was an inverse correlation between the serum E-2 levels and the pulsatility indices. There was a significant reduction in the pulsatility index in at least one of the four arteries after 2 months of HRT in all the treatment groups but not in the control group. The effect of HRT on the pulsatility index persisted until the completion of the study in all the treatment groups. Conclusion(s): These results confirm that the administration of HRT is associated with a reduction of the pulsatility index, and hence an increase in blood flow in the peripheral arteries; this change in the pulsatility index is related directly to serum E-2 levels. The percutaneous route of administration of estrogen was at least as effective as oral treatment in improving peripheral vascular flow velocity. The beneficial effect of estrogen was not affected by the addition of a progestogen. (Fertil Steril(R) 1998:70:284-8. (C)1998 by American Society for Reproductive Medicine.).
引用
收藏
页码:284 / 288
页数:5
相关论文
共 17 条
[1]   CARDIOVASCULAR MORTALITY AND NONCONTRACEPTIVE USE OF ESTROGEN IN WOMEN - RESULTS FROM THE LIPID RESEARCH CLINICS PROGRAM FOLLOW-UP-STUDY [J].
BUSH, TL ;
BARRETTCONNOR, E ;
COWAN, LD ;
CRIQUI, MH ;
WALLACE, RB ;
SUCHINDRAN, CM ;
TYROLER, HA ;
RIFKIND, BM .
CIRCULATION, 1987, 75 (06) :1102-1109
[2]   COMPARISON OF TRANSDERMAL AND ORAL ESTROGEN-PROGESTIN REPLACEMENT THERAPY - EFFECTS ON SERUM-LIPIDS AND LIPOPROTEINS [J].
CROOK, D ;
CUST, MP ;
GANGAR, KF ;
WORTHINGTON, M ;
HILLARD, TC ;
STEVENSON, JC ;
WHITEHEAD, MI ;
WYNN, V .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1992, 166 (03) :950-955
[3]  
GANGAR KF, 1991, LANCET, V338, P839
[4]   EFFECTS OF ESTROGEN REPLACEMENT THERAPY ON PERIPHERAL VASOMOTOR FUNCTION IN POSTMENOPAUSAL WOMEN [J].
GILLIGAN, DM ;
BADAR, DM ;
PANZA, JA ;
QUYYUMI, AA ;
CANNON, RO .
AMERICAN JOURNAL OF CARDIOLOGY, 1995, 75 (04) :264-268
[5]  
GISLARD V, 1988, J PHARMACOL EXP THER, V244, P19
[6]   HORMONE-THERAPY TO PREVENT DISEASE AND PROLONG LIFE IN POSTMENOPAUSAL WOMEN [J].
GRADY, D ;
RUBIN, SM ;
PETITTI, DB ;
FOX, CS ;
BLACK, D ;
ETTINGER, B ;
ERNSTER, VL ;
CUMMINGS, SR .
ANNALS OF INTERNAL MEDICINE, 1992, 117 (12) :1016-1037
[7]   A preliminary study on the effect of hormone replacement therapy on peripheral flow velocity in postmenopausal women [J].
Lau, TK ;
Chung, TKH ;
Haines, CJ .
MATURITAS, 1997, 26 (01) :53-56
[8]   ESTROGEN-MEDIATED CYTOPLASMIC AND NUCLEAR-DISTRIBUTION OF RAT CARDIOVASCULAR ESTROGEN-RECEPTORS [J].
LIN, AL ;
SHAIN, SA .
ARTERIOSCLEROSIS, 1985, 5 (06) :668-677
[9]  
LOBO RA, 1994, OBSTET GYNECOL, V84, P987
[10]   EFFECTS OF ESTROGEN OR ESTROGEN/PROGESTIN REGIMENS ON HEART-DISEASE RISK-FACTORS IN POSTMENOPAUSAL WOMEN - THE POSTMENOPAUSAL ESTROGEN/PROGESTIN INTERVENTIONS (PEPI) TRIAL [J].
MILLER, VT ;
LAROSA, J ;
BARNABEI, V ;
KESSLER, C ;
LEVIN, G ;
SMITHROTH, A ;
GRIFFIN, M ;
STOY, DB ;
BUSH, T ;
ZACUR, H ;
FOSTER, D ;
ANDERSON, J ;
MCKENZIE, A ;
MILLER, S ;
WOOD, PD ;
STEFANICK, ML ;
MARCUS, R ;
AKANA, A ;
HEINRICHS, L ;
KIRCHNER, C ;
OHANLAN, K ;
RUYLE, M ;
SHEEHAN, M ;
JUDD, HL ;
GREENDALE, G ;
BAYALOS, R ;
LOZANO, K ;
KAWAKAMI, K ;
BARRETTCONNOR, E ;
LANGER, R ;
KRITZSILVERSTEIN, D ;
CARRIONPETERSEN, ML ;
CAVERO, C ;
SCHROTT, HG ;
JOHNSON, SR ;
FEDDERSEN, DA ;
KRUTZFELDT, DL ;
BENDA, JA ;
PAUERSTEIN, C ;
TRABAL, J ;
SCHENKEN, R ;
STERN, MP ;
RODRIGUEZSIFUENTES, M ;
EASTON, C ;
WELLS, HB ;
ESPELAND, M ;
HOWARD, G ;
BYINGTON, R ;
LEGAULT, C ;
SHUMAKER, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (03) :199-208